Navigation Links
Cancer Diagnostics Market: Sales Forecasts, 2013 Shares & Competitive Strategies Research Reports

DALLAS, Aug. 19, 2013 /PRNewswire-iReach/ -- These comprehensive cancer diagnostics market research reports examine trends for the diagnostics market in US, UK, Spain, Japan, Italy, Germany and France including reviews of current and emerging tests, analysis of potential applications of various diagnostic technologies, sales forecasts of major tumor markers by country and market segment, profiles of leading market players and potential entrants as well as suggests alternative business expansion strategies for suppliers. The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.


Explore individual country specific cancer diagnostics market 2013 sales forecasts, supplier shares, competitive strategies report of your choice from the links below:

US report (620 pages, 103 tables) -

UK report (620 pages, 85 tables) -

Spain report (565 pages, 85 tables) -

Japan report (590 pages, 95 tables) -

Italy report (570 pages, 83 tables) -

Germany report (585 pages, 95 tables) -

France report (585 pages, 95 tables) -

Cancer diagnostics tests covered in these reports include: ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

These reports also cover information on current and emerging products and review of over 200 current and emerging cancer diagnostic tests including: Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines, Immunohistochemical Stains and others. The reports also provide analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices.

Competitive assessments in these reports include information on market players in the industry operating in US, UK, Spain, Japan, Italy, Germany and France. This analysis covers strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D. Business opportunities and strategic recommendations covered in this research studies include specific new product development opportunities with potentially significant market appeal during the next five years, design criteria for new products, alternative market penetration strategies and potential market entry barriers and risks.

Companies covered in these individual country focused cancer diagnostics market reports include: Abbott, AdnaGen, Agilent Technologies, Applied Gene Technologies, Arca / Nuvelo, Beckman Coulter / Danaher, Becton Dickinson, Biomedical Diagnostics, bioMerieux, Bio-Rad, CellSearch, Cepheid, Correlogic Systems / Vermillion, Decode, Diadexus, Diagnocure, Diasorin, Eiken Chemical, Epigenomics, Enterix, Enzo Biochem, Exact Sciences, Fujirebio / Innogenetics, Guided Therapeutics, Hologic / Gen-Probe, Kreatech, Kyowa Medex, Life Technologies, Mackay Life Sciences, Myriad Genetics, Nanogen Elitech, OncoLab, Ortho-Clinical Diagnostics, Panacea Pharmaceuticals, Polartechnics, Polymedco, PreMD, Qiagen / Ipsogen, Quest Diagnostics, Radient Pharmaceuticals, Roche, Scienion, Sequenom, Siemens Healthcare, Takara Bio, Targeted Diagnostics & Therapeutics, Tosoh, Veridex, Wako Pure Chemicals, Wallac/PE and Zila.

These research reports provide cancer diagnostics market segmentation analysis covering sales and market shares of major suppliers, by individual cancer diagnostic test as well as five-year test volume and sales forecasts for major cancer diagnostic tests by market segment, including hospitals and commercial / private laboratories. The segmentation analysis also includes review of the market dynamics, structure, size, growth and major suppliers with cancer statistics, etiology and recent developments.

For each of these seven countries, these reports provide technology review of the market including assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies with their potential applications for cancer diagnostic testing.  Review of competing / complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy is also included in these research studies. Extensive listings of over 500 companies, universities and research centers developing new cancer diagnostic tests and detection technologies is provided.

Explore more reports on cancer diagnostics market at .

About Us: is an online market research reports library of 250,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Media Contact: Priyank Tiwari, RnR Market Research, +1 888 391 5441,

News distributed by PR Newswire iReach:

SOURCE RnR Market Research
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. The Majority of Surveyed Oncologists Prescribe Avastin Off-label to Their Ovarian Cancer Patients; However Approximately Half Encounter Access and Reimbursement Hurdles
2. Berg Partners With Department of Defense Research Center and Military Medical Foundation to Advance Prostate Cancer Research
3. NW Bio Receives Regulatory Decision That Will Enable Its Phase III Brain Cancer Trial To Proceed In Germany
4. MultiCell Technologies and Genisphere Evaluate Targeted Delivery of MCT-485, a Noncoding miRNA for the Treatment of Cancer
5. The Foundation for Womens Cancer to Host 6th Annual Race for Awareness at Arlington Park
6. University of Virginia Cancer Center Begins Using New Telemedicine Technology for Cervical Cancer Screenings
7. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
8. NYU-Poly Nano Scientists Reach the Holy Grail in Label-Free Cancer Marker Detection: Single Molecules
9. Innovative Cancer Treatment Supported by NICE
10. Inovio Pharmaceuticals Potent hTERT DNA Cancer Vaccine Shows Potential to Reduce Tumors and Prevent Tumor Recurrence
11. Distinguished Cancer Investigator, Daniel Von Hoff, M.D., to Lead Cell Therapeutics Scientific Advisory Board
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015   Nuance Communications, Inc. ... National Decision Support Company (NDSC) today jointly announced ... collaboration capabilities that utilize the American College of Radiology,s ... provider organizations to comply with current and emerging ... --> By combining clinical decision support, ...
(Date:11/30/2015)... , Nov. 30, 2015  Novartis will demonstrate the ... 57 th American Society of Hematology (ASH) Annual ... myelomas as well as supportive care, including key findings ... personalized cell therapies. The ASH Annual Meeting will be ... . Novartis Oncology . "We will be ...
(Date:11/30/2015)... Israel , Nov. 30, 2015  OticPharma, Ltd., ... and developing innovative therapies for ear, nose, and throat ... A. Katkin as chairman of the company,s board ... executive officer for OticPharma, Ltd.  "Keith brings a wealth ... will be able to share this experience and provide ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Brenntag Specialties, Inc. (BSI) ... for the Nutraceutical Specialties products into oral solid dosage in the over the ... “We are pleased to announce our expanded distribution agreement with ASI.” said Steve ...
(Date:11/30/2015)... ... November 30, 2015 , ... An inventor from Charlottesville, Va., is ... "My last baby had high blood pressure due to loud noises," she said, "so ... babies from noise pollution as well as radio waves and microwaves." , The baby ...
(Date:11/30/2015)... ... November 30, 2015 , ... Since its ... specializing in independent living, assisted living and all other retirement options. Support for ... awareness and research remains a top priority. , So it’s no surprise ...
(Date:11/30/2015)... New York, New York (PRWEB) , ... November 30, 2015 , ... ... at the Greater New York Dental Meeting. Their Ecosystem empowers dentists to make complex ... Dentists who visit the booth will receive a free fee survey with 10 procedures ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... of DataTrade Solutions Inc., a Healthcare IT consulting, development and support company. The ... and technical experience available within DataTrade to extend the services currently provided by ...
Breaking Medicine News(10 mins):